Notice2022-09876
Foreign-Trade Zone (FTZ) 22-Chicago, Illinois; Notification of Proposed Production Activity; AbbVie, Inc.; (Pharmaceutical Products); Chicago, Illinois
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 9, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 89 (Monday, May 9, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 89 (Monday, May 9, 2022)]
[Notices]
[Page 27563]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-09876]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-18-2022]
Foreign-Trade Zone (FTZ) 22--Chicago, Illinois; Notification of
Proposed Production Activity; AbbVie, Inc.; (Pharmaceutical Products);
Chicago, Illinois
AbbVie, Inc., submitted a notification of proposed production
activity to the FTZ Board (the Board) for its facilities in Chicago,
Illinois within Subzone 22S. The notification conforming to the
requirements of the Board's regulations (15 CFR 400.22) was received on
April 29, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material and specific finished
product described in the submitted notification (summarized below) and
subsequently authorized by the Board. The benefits that may stem from
conducting production activity under FTZ procedures are explained in
the background section of the Board's website--accessible via
<a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished product and material would be
added to the production authority that the Board previously approved
for the operation, as reflected on the Board's website.
The proposed finished product is prolinamide tablets (duty-free).
The proposed foreign-status material is prolinamide active
pharmaceutical ingredient (duty rate 3.7%).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#791f0d03390d0b181d1c571e160f"><span class="__cf_email__" data-cfemail="3d5b49477d494f5c5958135a524b">[email protected]</span></a>. The closing period for their receipt is June 21, 2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#7132190318025f2614151514031304031f3105031015145f161e07"><span class="__cf_email__" data-cfemail="bcffd4ced5cf92ebd9d8d8d9cedec9ced2fcc8ceddd8d992dbd3ca">[email protected]</span></a>.
Dated: May 4, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-09876 Filed 5-6-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 9, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.